Novo Nordisk and AI-focused Valo Health have announced an expanded collaboration to accelerate the discovery and development of treatments for obesity, type 2 diabetes, and cardiovascular disease. The partnership leverages Valo’s Opal Computational Platform™, which uses artificial intelligence and extensive human data to drive drug discovery, alongside Novo Nordisk’s expertise in cardiometabolic diseases.
According to a press release, the original agreement, launched in September 2023, covered up to 11 drug programs primarily focused on cardiovascular disease, with Valo eligible for up to $2.7 billion in milestone payments. The expanded agreement increases the scope to 20 drug programs, adding nine new projects. Valo will receive an upfront payment, equity investment, and a near-term milestone payment totaling $190 million, with the potential to earn up to $4.6 billion in milestone payments, plus R&D funding and royalties.
Marcus Schindler, Executive Vice President and Chief Scientific Officer at Novo Nordisk, stated that the collaboration has already demonstrated the power of combining Novo Nordisk’s scientific expertise with Valo’s AI-driven platform. He noted that the expansion will allow a sharper focus on obesity and type 2 diabetes, in addition to cardiovascular disease, enabling the discovery of novel therapeutic targets and advancing multiple AI-powered programs.
Valo CEO Brian Alexander highlighted the significance of the partnership, emphasizing its potential to transform cardiometabolic disease treatment through human-centric AI. He explained that the Opal Platform uses real-world patient data and preclinical human models to identify, validate, and develop small molecule therapies with improved safety and efficacy.
The partnership underscores the potential of AI in reshaping drug discovery and development, aiming to deliver faster, more effective solutions to address some of the most pressing global health challenges.
